GlassScriptPhysician profile
Caroline S Mcsween
NPI 1891190617
$2,605.90
in general payments reported to CMS, 2019-2025
23 companies · $652 in 2025
The $652 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $432 · 2022: $669 · 2023: $458 · 2024: $395 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $761.90 | 2021-2025 | |
| Glaxosmithkline, LLC. | $317.47 | 2021-2025 | Trelegy Ellipta, Shingrix, Nucala |
| Novo Nordisk INC | $297.62 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $176.97 | 2021-2025 | Airsupra, Farxiga |
| Pfizer INC. | $147.21 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.17 | 2022-2025 | Xifaxan |
| Lilly USA, LLC | $121.26 | 2021-2023 | Mounjaro |
| Amgen INC. | $88.14 | 2021-2024 | Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.99 | 2022-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $76.05 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $49.81 | 2023-2025 | Myrbetriq, Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.37 | 2021 | |
| Xeris Pharmaceuticals, INC. | $40.74 | 2024-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $37.46 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $36.93 | 2023-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $27.10 | 2023 | |
| Dexcom, INC. | $27.06 | 2025 | Dexcom G6 Transmitter |
| Baxter Healthcare | $25.04 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Abbott Laboratories | $24.67 | 2021 | |
| Shield Therapeutics INC | $23.73 | 2025 | |
| Alkermes, INC. | $21.67 | 2022 | |
| Merck Sharp & Dohme LLC | $15.38 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.16 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Mcsween listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.